Litcius/Paper detail

Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy

Xintong Li, Zhe Li, Hanyang Yu

2020Chemical Communications67 citationsDOI

Abstract

Threose nucleic acid (TNA) aptamers were selected in vitro to bind PD-L1 protein and inhibit its interaction with PD-1. These biologically stable TNA aptamers bound target proteins with nanomolar affinities, and effectively blocked PD-1/PD-L1 interaction in vitro. After injection into a colon cancer xenograft mouse model, the TNA aptamer N5 was specifically accumulated at the tumour site, and significantly inhibited tumour growth in vivo.

Topics & Concepts

AptamerNucleic acidIn vitroChemistryImmunotherapyCancer immunotherapyComputational biologySelection (genetic algorithm)Systematic evolution of ligands by exponential enrichmentBlock (permutation group theory)CancerCombinatorial chemistryMolecular biologyBiochemistryBiologyRNAGeneticsComputer scienceGeneMathematicsGeometryArtificial intelligenceAdvanced biosensing and bioanalysis techniquesImmunotherapy and Immune ResponsesNanoplatforms for cancer theranostics
Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy | Litcius